Williams Alan L, Newman Raquelle S
Department of Family Medicine, Uniformed Services University, Bethesda, Maryland
Spangdahlem Air Base, 54529 Spangdahlem, AE, Germany.
Ann Fam Med. 2025 Mar 24;23(2):162-164. doi: 10.1370/afm.240184.
Confidence in hepatitis B seroprotection for US health care workers includes a complete immunization series followed by a hepatitis B surface antigen antibody (anti-HBs) titer ≥10 mIU/mL. We compared standard hepatitis B vaccines to Heplisav-B (Dynavax Technologies Corp) as a single booster for young, healthy, previously vaccinated individuals. Participants (N = 242) had documentation of a single vaccination series and an anti-HBs titer <10 mIU/mL. In this cohort, 1 booster achieved seropositivity for 92.7% (95% CI, 84.8%-97.2%) of the standard hepatitis B vaccine group and 99.4% (95% CI, 96.6%-100.0%) of the Heplisav-B group. Both boosters are likely to produce seropositivity in this population.
美国医护人员对乙肝血清保护的信心包括完整的免疫接种系列，随后乙肝表面抗原抗体（抗-HBs）滴度≥10 mIU/mL。我们将标准乙肝疫苗与Heplisav-B（Dynavax Technologies Corp）作为年轻、健康、先前已接种疫苗个体的单一加强剂进行了比较。参与者（N = 242）有单次接种系列的记录且抗-HBs滴度<10 mIU/mL。在这个队列中，1剂加强针使标准乙肝疫苗组92.7%（95% CI，84.8%-97.2%）的人和Heplisav-B组99.4%（95% CI，96.6%-100.0%）的人实现了血清阳性。两种加强针都可能使该人群产生血清阳性。
